Peptilogics Receives FDA Orphan Drug Designation for Novel Peptide Therapy for the Treatment of Prosthetic Joint Infections
Peptilogics, a biotechnology platform company leveraging computational design to discover novel peptide therapeutics, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for PLG0206, the company’s first-in-class, broad-spectrum antibiotic peptide, for the treatment of prosthetic joint infections (PJI), a rare life-threatening condition that may result from arthroplasty or joint replacement procedures.
“PLG0206 is the first novel anti-infective to be granted Orphan Drug Designation, confirmation that we are advancing a meaningful therapy that can address an unmet medical need, beginning with PJI,” said Jonathan Steckbeck, PhD, Founder and CEO of Peptilogics. “This advance, combined with recent enhancements to our discovery platform, are enabling faster development of novel peptide therapies against any targets of interest, putting Peptilogics in a unique position to respond to the evolving landscape of infectious pathogens as well as other diseases worldwide.”
Registration now open:
International Masterclass AMR 29 SEP delivered digitally: 2 = 1!
- Science, Health-Economic & Societal impact
- Global causes and global solutions
- Bottom-up, interactive approach
- International Experts involved